Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · patients with laparoscopic cholecystectomy.
It is very uncertain whether day‐surgery changes serious adverse events compared with overnight stay surgery (very low certainty).
1 finding from 1 review
Serious adverse events · People with P. vivax malaria1
1 finding from 1 review
Serious adverse events · people with bronchiectasis
28 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off placebo regimen (low certainty).
1 finding from 1 review
OR 1 [0.68, 1.46]
Studies not reported
Low
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 28 days on/off antibiotic regimen (moderate certainty).
1 finding from 1 review
OR 0.83 [0.37, 1.86]
Studies not reported
Moderate
Serious adverse events · people with bronchiectasis
14 days on/off antibiotic regimen showed no clear difference in serious adverse events compared with 14 days on/off placebo regimen (high certainty).
1 finding from 1 review
OR 0.92 [0.63, 1.33]
Studies not reported
High
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Serious adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 40 mg/day probably leads to higher serious Adverse Events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · patients with chronic cout
Febuxostat 120 mg/day showed no clear difference in serious Adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in serious Adverse Events compared with allopurinol (high certainty).
1 finding from 1 review
Serious adverse events · postmenopausal women with a higher risk for fracturesa
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with mefloquine plus artesunate (MQ + AS) (low certainty).
1 finding from 1 review
Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria
Pyronaridine‐artesunate (PY‐AS) showed no clear difference in serious adverse events (42 days) compared with artemether‐lumefantrine (AL) (low certainty).
1 finding from 1 review
Serious adverse events by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Serious adverse events by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)
Bamlanivimab showed no clear difference in serious adverse events by day 30 compared with placebo (low certainty).
1 finding from 1 review